Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | LTA4H | P09960 | 2/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13486398 | 0.79 | PDE4B (0.34) | PDE4BLTA4HDPP4 | |
| SCHEMBL19366756 | 0.79 | PDE4B (0.34) | PDE4BLTA4HDPP4 | |
| SCHEMBL19366754 | 0.79 | PDE4B (0.34) | PDE4BLTA4HDPP4 | |
| SCHEMBL22370669 | 0.74 | LTA4H (0.32) | PDE4BLTA4HDPP4 | |
| SCHEMBL22370566 | 0.74 | LTA4H (0.32) | PDE4BLTA4HDPP4 | |
| SCHEMBL22370564 | 0.74 | LTA4H (0.32) | PDE4BLTA4HDPP4 | |
| SCHEMBL22388078 | 0.74 | PIK3CD (0.41) | PDE4BLTA4HDPP4 | |
| SCHEMBL21124544 | 0.73 | — | — | |
| SCHEMBL20940079 | 0.71 | LTA4H (0.40) | PDE4BLTA4HPDE4DDPP4 | |
| SCHEMBL15451877 | 0.70 | LTA4H (0.41) | PDE4BLTA4HPDE4DDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | PDE4B 1040/4885LTA4H 1941/4885PDE4D 1401/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | PDE4B 1040/4885LTA4H 1941/4885PDE4D 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.